Leapcure's oncology recruitment engine has enrolled 1,000+ patients across 50,000+ engaged, built to move fast on Refractory Melanoma's narrower, more time-sensitive patient population.

We bring an oncology recruitment engine and a melanoma-specific advocacy and physician network, built through our uveal melanoma program, alongside a Patient Success Team trained to support families with sensitivity while quickly assessing eligibility.

Talk to our refractory melanoma teamSee how it works →
50,000+
Patients engaged
across Leapcure's oncology portfolio
23
Advocacy partnerships
active in Leapcure's uveal melanoma program
2x
Site consenting rate improvement
in a completed oncology gene therapy program
48 hrs
To mobilize advocacy and physician networks
existing oncology relationships

Understanding Refractory Melanoma as a Clinical Trial Indication

Refractory melanoma is unresectable or metastatic melanoma that has progressed after standard first-line therapy, typically anti-PD-1 with or without anti-CTLA-4. These patients have already exhausted the standard options, so trials of next-line and investigational therapies are often the most meaningful path available, and enrollment is genuinely time-sensitive: as disease progresses, the pool of patients who remain eligible and well enough to participate narrows week by week.

For sponsors, that combination is what makes refractory melanoma recruitment hard. The eligible population is narrower than earlier-line studies, it is defined by prior-therapy history and progression that must be confirmed, and it is under time pressure that a slow, volume-led approach cannot meet. Reaching these patients and their families with sensitivity, while assessing eligibility quickly enough that no time is lost, is the real work.

Leapcure brings an oncology recruitment engine built for exactly that. Across its portfolio, Leapcure has engaged 50,000+ patients and enrolled 1,000+ across multiple cancer indications, and already operates melanoma recruitment relationships through our uveal melanoma program, where 23 advocacy partners are active. Those melanoma-specific relationships come from the uveal melanoma program, while the broader enrollment figures are oncology-wide track record; together they are the infrastructure Leapcure applies to a refractory melanoma study, mobilized within 48 hours of program launch.

The Challenge

Refractory melanoma recruitment is defined by a narrow, time-sensitive pool of patients who have already exhausted standard options. Speed, eligibility confirmation, and sensitivity all have to be solved at once.

A narrow eligible pool that shrinks with every week of delay

Refractory melanoma trials enroll patients who have already progressed after first-line therapy, an inherently smaller population, and disease progression steadily removes patients who would otherwise qualify. Slow enrollment does not just cost time; it costs eligible patients.

Leapcure mobilizes existing oncology advocacy and physician relationships within 48 hours of program launch, so a shrinking eligible pool is not lost to a slow campaign ramp.

Eligibility is defined by prior therapy and confirmed progression

Refractory populations are gated on treatment history and documented progression after anti-PD-1, with or without anti-CTLA-4. Confirming that history before referral is its own recruiting task, and one that generic outreach skips.

Leapcure pre-screens referrals against protocol eligibility before they reach a site; in a completed oncology gene therapy program this discipline doubled site consenting rates.

Patients and families have already run out of standard options

By the time a patient is eligible for a refractory melanoma trial, they and their families are navigating a serious, advanced diagnosis. Recruitment that ignores that reality loses patients who need sensitivity as much as speed.

Leapcure's Patient Success Team is trained to support families with sensitivity as they explore trial options, while helping quickly assess eligibility so no time is lost.

Melanoma patients are reached through trusted relationships, fast

A time-sensitive study cannot wait for a cold campaign to warm up. Reaching melanoma patients means activating existing advocacy and physician relationships immediately, not building them from scratch per study.

Through Leapcure's uveal melanoma program, 23 advocacy partnerships are already active, melanoma-wide relationship experience Leapcure applies to refractory melanoma rather than building from scratch.

Three steps. One strategy built for your refractory melanoma trial.

Leapcure applies its oncology recruitment engine and existing melanoma relationships to your protocol, moving fast on a narrow, time-sensitive population and confirming eligibility before referral.

1

Mobilize oncology advocacy, physician, and digital channels

We activate existing oncology advocacy and physician relationships, melanoma relationships built through our uveal melanoma program, and precision digital, within 48 hours of program launch. On a time-sensitive study, starting from existing relationships rather than a cold build is what protects the eligible pool.

2

Pre-screen for prior therapy, progression, and eligibility

Every referral is engaged and pre-screened before a site sees the patient. We confirm prior-therapy history and documented progression against protocol criteria so sites receive eligible, documentation-ready patients, the same pre-screening discipline that doubled site consenting rates on a completed oncology gene therapy program.

3

Support families to the site and optimize continuously

Our Patient Success Team supports patients and families with sensitivity through a serious diagnosis while moving them quickly through eligibility, then we track referral quality and site capacity and rebalance channels toward where enrollment can move fastest.

An oncology recruitment engine, and melanoma relationships built through our uveal melanoma program.

Oncology scale

50,000+ patients engaged and 1,000+ enrolled across multiple cancer indications.

Gene therapy program

27 advocacy partnerships activated and 20+ patients queued in four months, with site consenting rates doubled.

Melanoma relationships

23 advocacy partnerships active in Leapcure's uveal melanoma program, applied to refractory melanoma.

Mobilization speed

Existing oncology advocacy and physician relationships mobilized within 48 hours of program launch.

Four capabilities. Built across oncology and melanoma. Ready for refractory melanoma.

Leapcure reaches and qualifies refractory melanoma patients through an oncology recruitment engine, existing melanoma relationships, pre-screening built for a narrow time-sensitive pool, and answer-engine visibility delivered to your trial.

Oncology Recruitment Engine

  • •An oncology recruitment engine proven across multiple cancer indications, with 50,000+ patients engaged and 1,000+ enrolled.
  • •The same pre-screening and patient-support model doubled site consenting rates on a completed oncology gene therapy program.
  • •It is built to move fast on a narrow, time-sensitive population, mobilizing existing relationships rather than building a campaign from scratch.

Melanoma Advocacy and Physician Relationships

  • •Through our uveal melanoma program, 23 advocacy partnerships are already active, melanoma-wide relationship experience applied to refractory melanoma.
  • •Existing oncology advocacy and physician relationships can be mobilized within 48 hours of program launch, rather than built from scratch per study.
  • •Starting warm is what protects a shrinking, time-sensitive eligible pool.

Pre-Screening for a Narrow, Time-Sensitive Pool

  • •Every referral is pre-screened for prior-therapy history, documented progression, and protocol eligibility before a site sees the patient.
  • •A Patient Success Team trained to support families with sensitivity moves them quickly through eligibility so no time is lost.
  • •Sites receive eligible, documentation-ready patients, not raw volume that fails late.

Answer-Engine and AI-Search Visibility

  • •Melanoma patients and caregivers increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
  • •This puts your refractory melanoma study where high-intent patients and caregivers are already searching.

Living with refractory melanoma? A clinical trial may be an option.

If you or someone you care for is living with melanoma that has progressed after standard treatment, a clinical trial may offer access to investigational therapies that are not yet widely available. We know an advanced diagnosis is hard, and that time matters. Leapcure's Patient Success Team supports you and your family with sensitivity, answers your questions honestly, and helps assess eligibility quickly so no time is lost.

See if a refractory melanoma trial may be right for you
Leapcure kangaroo mascot

Leapcure brings an oncology recruitment engine, 50,000+ patients engaged and 1,000+ enrolled, plus melanoma advocacy and physician relationships built through our uveal melanoma program, mobilized within 48 hours of launch and built to move fast on refractory melanoma's narrow, time-sensitive population. Talk to our refractory melanoma team about your active or upcoming study.

Talk to our refractory melanoma team